SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Elucidating the Spatial and Temporal Dynamics of Acute Myeloid Leukemia Progression Using Functional Omics and High-Throughput In Vivo Screening

This project aims to explore the spatial and temporal dynamics of tumor progression in Acute Myeloid Leukemia to identify critical factors influencing cancer pathogenicity and potential therapeutic targets.

Subsidie
€ 1.994.500
2024

Projectdetails

Introduction

Advances in sequencing-based phylogenetic studies applied to cancer evolution have led to the observation that the linear accumulation of oncogenic alterations over individuals’ lifespan does not match the late life pattern of cancer incidence. It has thus become clear that beyond the sequential accumulation of oncogenic driver mutations, additional factors also support cancer outgrowth.

Key Factors in Cancer Evolution

The temporal and spatial dynamics of tumor evolution represent two of the most critical mutation-independent variables to consider. Hence, we hypothesized that the dual features of aging and spatial dissemination promote critical fitness gains that are at least as significant as driver mutations in cancer.

Project Goals

The goal of this proposal is to investigate the spatial and temporal determinants of tumor progression and to dissect the contributions of these processes to cancer pathogenicity.

Disease Model

Due to its quite unique occurrence pattern and propagation characteristics, Acute Myeloid Leukemia (AML) is the prototypical disease model that we have elected to template such spatiotemporal-dependent features of disease development.

Methodology

To study these features, we engineered two mouse models of leukemia dissemination and aging using serially-transplantable MLL-AF9-driven leukemic blasts. Using these two models, we propose to:

  1. Combine metabolomic- and epigenomic-based profiling to portray the spatiotemporal dynamics of leukemia growth.
  2. Deploy single-cell transcriptomics coupled with lineage tracing experiments to reveal the pre-deterministic attributes of such dynamics.
  3. Leverage innovative multimodal in vivo shRNA and CRISPRa screening approaches to pinpoint and functionally characterize the critical age- and dissemination-related effector genes involved in leukemic progression.

Potential Impact

The comprehensive analysis of their unknown function will potentially define new therapeutic routes in AML, and, given the holistic nature of the spatiotemporal characteristics studied, in other cancers as well.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.994.500
Totale projectbegroting€ 1.994.500

Tijdlijn

Startdatum1-3-2024
Einddatum28-2-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEpenvoerder

Land(en)

France

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Unmasking the dynamic influence of the hematopoietic niche as an oncogenic path to myeloid neoplasms evolution

This project aims to explore hematopoietic-niche interactions across myeloid neoplasm stages to develop innovative therapies that prevent acute myeloid leukemia and improve patient outcomes.

ERC Starting...€ 1.911.428
2024
Details

Mechanistic models of leukemia-niche interaction using multimodal single cell profiling

This project aims to uncover AML's interactions with the bone marrow niche through advanced single-cell sequencing and modeling, potentially transforming treatment strategies for hematological malignancies.

ERC Consolid...€ 2.000.000
2022
Details

PLASTicity of Endothelial Cell as new Target for acute myeloId leukemia TherapY

This project aims to investigate embryonic-like endothelial cells in acute myeloid leukemia to identify therapeutic targets that enhance treatment responses and improve patient outcomes.

ERC Starting...€ 1.499.000
2024
Details

Understanding Diagnosing and Early intervention in the Myeloid malignancy Continuum

The Shlush lab aims to improve early diagnosis and treatment of myeloid malignancies by developing advanced diagnostic tools, exploring preleukemic mutations, and identifying targeted therapies.

ERC Consolid...€ 2.000.000
2025
Details

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

This project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance.

ERC Starting...€ 1.882.440
2024
Details
ERC Starting...

Unmasking the dynamic influence of the hematopoietic niche as an oncogenic path to myeloid neoplasms evolution

This project aims to explore hematopoietic-niche interactions across myeloid neoplasm stages to develop innovative therapies that prevent acute myeloid leukemia and improve patient outcomes.

ERC Starting Grant
€ 1.911.428
2024
Details
ERC Consolid...

Mechanistic models of leukemia-niche interaction using multimodal single cell profiling

This project aims to uncover AML's interactions with the bone marrow niche through advanced single-cell sequencing and modeling, potentially transforming treatment strategies for hematological malignancies.

ERC Consolidator Grant
€ 2.000.000
2022
Details
ERC Starting...

PLASTicity of Endothelial Cell as new Target for acute myeloId leukemia TherapY

This project aims to investigate embryonic-like endothelial cells in acute myeloid leukemia to identify therapeutic targets that enhance treatment responses and improve patient outcomes.

ERC Starting Grant
€ 1.499.000
2024
Details
ERC Consolid...

Understanding Diagnosing and Early intervention in the Myeloid malignancy Continuum

The Shlush lab aims to improve early diagnosis and treatment of myeloid malignancies by developing advanced diagnostic tools, exploring preleukemic mutations, and identifying targeted therapies.

ERC Consolidator Grant
€ 2.000.000
2025
Details
ERC Starting...

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

This project aims to develop a single-cell multiomics method to understand epigenetic resistance mechanisms in AML, enhancing treatment strategies against drug resistance.

ERC Starting Grant
€ 1.882.440
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.